LifeVantage Corporation

LFVN

US53222K2050

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
6.41 ^USD	+0.31%		+7.19%	+6.83%

05-02	Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q3 Revenue $48.2M, vs. Street Est of $52.2M	MT
05-02	Transcript : LifeVantage Corporation, Q3 2024 Earnings Call, May 02, 2024

LifeVantage Corporation Appoints Shawn Talbott as New Global Chief Science Officer, Effective January 6, 2014

January 07, 2014 at 09:00 am

LifeVantage Corporation announced that Shawn Talbott, Ph.D. has accepted the role of Global Chief Science Officer for the company effective January 6, 2014.

Latest news about LifeVantage Corporation

Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q3 Revenue $48.2M, vs. Street Est of $52.2M	05-02	MT
Transcript : LifeVantage Corporation, Q3 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q3 EPS $0.21, vs. Street Est of $0.16	05-02	MT
LifeVantage Corporation Declares Quarterly Dividend, Payable on June 14, 2024	05-02	CI
Tranche Update on LifeVantage Corporation's Equity Buyback Plan announced on November 27, 2017.	05-02	CI
LifeVantage Corporation Revises Earnings Guidance for the Fiscal Year 2024	05-02	CI
LifeVantage Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-02	CI
LifeVantage Corporation Enters Loan Agreement with Bank of America, N.A	04-16	CI
Transcript : LifeVantage Corporation - Special Call	03-20
LifeVantage Corporation Announces the Launch of its TrueScience Activated Skin Care Collection	03-04	CI
Bradley Louis Radoff and Sudbury Capital Management Enter into Cooperation Agreement with LifeVantage Corporation	02-15	CI
LifeVantage Corporation Appoints Dayton Judd to Its Board of Directors, Audit Committee and the Nominating and Corporate Governance Committee	02-15	CI
LifeVantage Corporation Announces Expansion of LV360 into Canada, Mexico, and European Markets	02-07	CI
Lifevantage Keeps Quarterly Cash Dividend at $0.035 a Share, Payable March 15 to Holders of Record March 1	01-30	MT
Transcript : LifeVantage Corporation, Q2 2024 Earnings Call, Jan 30, 2024	01-30
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q2 Revenue $51.6M, vs. Street Est of $54.6M	01-30	MT
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q2 EPS $0.10	01-30	MT
LifeVantage Corporation Provides Earnings Guidance for the Fiscal Year 2024	01-30	CI
Tranche Update on LifeVantage Corporation's Equity Buyback Plan announced on November 27, 2017.	01-30	CI
LifeVantage Corporation Declares Quarterly Dividend, Payable on March 15, 2024	01-30	CI
LifeVantage Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	01-30	CI
Key Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Thursday	11-30	MT
Lifevantage Says Protandim Nrf2-TrueScience Combination Helps Cells 'Accurately' Respond To Stress Levels	11-29	MT
LifeVantage Corporation Announces Executive Changes	11-27	CI
Bradley Louis Radoff and Sudbury Capital Management?s Counsel Delivers a Letter to Counsel to LifeVantage Corporation	11-14	CI

LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, hair, bath and body, and targeted relief products. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smartweight management system, which includes PhysIQ Fat Burn and PhysIQ Prebiotic, all formulated to aid in weight management.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIFEVANTAGE CORPORATION	+6.83%	81.16M
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals